Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5466800 | 0.82 | PKM (0.52) | METLMNAALDH1A1HTT | |
| SCHEMBL25754769 | 0.82 | NPC1 (0.57) | LMNAKMT2AMEN1ALDH1A1ACHE | |
| SCHEMBL18398687 | 0.81 | KMT2A (0.58) | METLMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL25754716 | 0.76 | NR1H3 (0.52) | LMNAKMT2AMEN1ALDH1A1ACHE | |
| SCHEMBL25754713 | 0.76 | LMNA (0.50) | LMNAKMT2AMEN1ALDH1A1ACHE | |
| SCHEMBL25754768 | 0.76 | ACHE (0.51) | LMNAKMT2AMEN1ALDH1A1ACHE | |
| SCHEMBL5466433 | 0.76 | LMNA (0.55) | LMNAKMT2AMEN1ALDH1A1ACHE | |
| SCHEMBL5472525 | 0.73 | LMNA (0.52) | LMNAKMT2AMEN1ALDH1A1ACHE | |
| SCHEMBL12415871 | 0.72 | MEN1 (0.52) | LMNAKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL5475935 | 0.71 | LMNA (0.55) | LMNAKMT2AMEN1ALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | MET 3453/4885LMNA 2632/4885KMT2A 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.